Results from the CO-PILOT study also bode well for VRTX' oral combo (Incivek + VX-222 +Riba) although if memory serves SVR4 there were nowhere near those from CO-PILOT.
In particular if SVR rates are lower for the VRTX combo relative to other HCV DAA combos, I just don't see how that combo will successfully compete down the road against the other combos that contain all QD components.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.